Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

In this interview with Chovatiya, he highlights some of the elements of the presentations being given at the Fall Clinical Dermatology conference in Las Vegas.


What To Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD

Given the distrust some patients with conditions such as alopecia areata and psoriasis have regarding JAK inhibitors, this analysis highlights several approaches to such concerns.

Study Identifies Approaches to Address Patient Fears Regarding JAK Inhibitor Safety

New data presented by Sun Pharma at EADV 2024 highlight the impact of deuruxolitinib 8 mg treatment of adults with severe alopecia areata.

Deuruxolitinib Twice-Daily Improves Hair Satisfaction Among Patients with Alopecia Areata

Shapiro spoke in his Maui Derm NP+PA Fall conference interview about differentiating between types of alopecia areata and about the potential use of JAK inhibitors.


Differentiating Between Different Types of Alopecia, with Jerry Shapiro, MD

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

Coping Methods, Lack of Support Are Predictors of Self-Stigma for Patients with Skin Disease

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

JAK Inhibitor Improves Autoimmune Conditions in Down Syndrome

Withdrawal of baricitinib in severe alopecia areata led to hair loss in 80% of patients, highlighting the need for ongoing therapy to maintain regrowth.

Baricitnib Withdrawal Leads to Loss of Benefit in Up to 80% with Alopecia Areata

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

Alopecia Areata Increases Risk of Psychiatric and Autoimmune Comorbidities

Brett King, MD, PhD, discusses how the deuruxolitinib approval impacts the treatment landscape of alopecia areata.

Brett King, MD: Deuruxolitinib Approval and the 'Golden Age' of Alopecia Areata 

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.